Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Investors & Media
  • Contact
    Top Links
    • Investors & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Ziftomenib
      • Tipifarnib
      • KO-2806
      • Scientific Publications
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Clinical Trials
      • Overview of Clinical Trials
      • Ziftomenib Clinical Trials
      • KOMET-001 – AML
      • Tipifarnib Clinical Trials
      • AIM-HN – HNSCC
      • KURRENT-HN – HNSCC
      • KURRENT-LUNG
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Investors & Media
    • Contact
    • MenuMenu

    Press Release

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts

    Kura Oncology to Participate in Upcoming Investor Conferences

    03-01-2023
    PDF Version

    SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

    • A “Leukemia Corporate Panel” discussion at the Cowen Health Care Conference in Boston at 12:50 p.m. ET / 9:50 a.m. PT on March 8, 2023;

    • A fireside chat at the Cowen Health Care Conference at 2:50 p.m. ET / 11:50 a.m. PT on March 8, 2023; and

    • A fireside chat at the Barclays Global Healthcare Conference in Miami at 2:35 p.m. ET / 11:35 a.m. PT on March 14, 2023.

    Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following the events.

    About Kura Oncology

    Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.

    Contacts

    Investors:
    Pete De Spain
    Senior Vice President, Investor Relations &
    Corporate Communications
    (858) 500-8803
    pete@kuraoncology.com

    Media:
    Alexandra Weingarten
    Senior Manager, Corporate Communications
    (858) 500-8822
    alexandra@kuraoncology.com

     


    Primary Logo

    Source: Kura Oncology, Inc.

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Scientific Publications
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    Footer Links - Clinical Trials
    • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • Tipifarnib Clinical Trials
    • AIM-HN – HNSCC
    • KURRENT-HN – HNSCC
    • KURRENT-LUNG
    Footer Links - Investors
    • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc.
    12730 High Bluff Drive, Suite 400
    San Diego, CA 92130
    (858) 500-8800

    Kura Oncology, Inc.
    2 Seaport Lane, Suite 8A
    Boston, MA 02210
    (617) 588-3755

    Kura Oncology, Inc.
    5510 Morehouse Drive, Suite 110
    San Diego, California 92121

    © 2023 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy

    Scroll to top